ABT stock news · Abbott Laboratories

Abbott Announces Positive 30-Day Results from TECTONIC Clinical Trial for SonicForce™ Coronary IVL System

Catheter Precision shares a study showing its LockeT device works better than Abbott's Perclose device.

A study of 172 patients found more complications and device failures with Abbott's Perclose than LockeT, with equal efficiency. This raises concerns about Perclose's standing.

Abbott Laboratories shared the details from their earnings call for the third quarter of 2026.

Abbott's third-quarter sales rose 7% and earnings per share rose 9%. The planned nutrition-business split and expected later growth make the report favorable, despite legal and payment concerns.

Abbott Laboratories says it will create a new company for its nutrition business.

Abbott plans to make its global nutrition business a separate public company. The filing gives no timing or expected financial results, so it does not show a clear change for Abbott.

Abbott Laboratories shares how they did financially in the third quarter of 2026.

Abbott announced its third-quarter results and explained its adjusted profit measures. The supplied text gives no results figures, so it does not change how we read Abbott.

Here’s how you can make $500 a month from Abbott stock before their Q3 report.

Abbott’s article gives estimates for its coming report and explains its current dividend. It reports no new results or dividend change, so it does not shift the company’s outlook.

Rep. Rick Allen sold as much as $50K in Rollins stock; here’s what to understand.

Rep. Allen's reported $15,001–$50,000 sale of Abbott shares is a personal disclosure and the article says sales can reflect many reasons.

Abbott opts to resolve ongoing litigation regarding premature infant formula by agreeing to a $670 million settlement.

Abbott Laboratories has opted to settle ongoing litigation concerning its specialty infant formulas for premature babies, agreeing to pay $670 million to resolve claims linked to necrotizing enterocolitis. This decision, made in light of a significant jury verdict against the company, is expected to reduce future legal risks and may positively influence investor confidence in Abbott's stock.